Allergic reactions to the Ad26.COV2.S vaccine in South Africa

BACKGROUND: The Janssen-Ad26.COV2.S vaccine is authorized for use in several countries, with more than 30 million doses administered. Mild and severe allergic adverse events following immunization (AEFI) have been reported. OBJECTIVE: We sought to detail allergic reactions reported during the Sisonk...

Descripción completa

Detalles Bibliográficos
Autores principales: Peter, Jonny, Day, Cascia, Takuva, Simbarashe, Takalani, Azwidihwi, Engelbrecht, Imke, Garrett, Nigel, Goga, Ameena, Louw, Vernon, Opie, Jessica, Jacobson, Barry, Sanne, Ian, Gail-Bekker, Linda, Gray, Glenda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509997/
https://www.ncbi.nlm.nih.gov/pubmed/37780073
http://dx.doi.org/10.1016/j.jacig.2021.12.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509997/
https://www.ncbi.nlm.nih.gov/pubmed/37780073
http://dx.doi.org/10.1016/j.jacig.2021.12.002

Ejemplares similares